Xiao‐Peng Wang

Xiao‐Peng Wang

Auto-generated profile, based on publicly available information

Xiao‐Peng Wang

Medical School of Chinese PLA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2025 in European Journal of Neurology
Verified
Journal Article
Open access
JLJing‐Jie Li
Jing‐Jie Li
XWXiao‐Peng Wang
Xiao‐Peng Wang
QWQian‐Nan Wang
Qian‐Nan Wang
ZKZi‐Qing Kong
Zi‐Qing Kong
CHCong Han
Cong Han
LDLian Duan
Lian Duan
Background: Stroke in children is a global epidemic.Methods: Data on stroke, including incidence, DALYs, mortality, and associated risk factors from 1990 to 2021, were obtained from the Global Burden of Disease (GBD) study, 2021. Estimated annual percentage changes were calculated to evaluate changes in the age‐standardized rates of incidence (ASIR), DALYs (ASDR), and mortality (ASMR), as well as trends by age, sex, and sociodemographic index (SDI). Projections of DALYs to 2050 were made.Results: In 2021, there were 310,133 incident stroke cases, accounting for 24,807 deaths and 2,414,655 DALYs among children and adolescents. The global ASIR, ASDR, and ASMR for stroke were 11.8, 93.9, and 1.0 per 100,000 population, respectively. Middle‐to‐low‐SDI regions accounted for 81.6% of incident cases, 90.2% of DALYs, and 92.7% of deaths. A reversed V‐shaped association was observed between SDI and ASRs. Children < 1 year had the highest ASRs, with rates generally decreasing with age, and the highest incidence of hemorrhagic stroke. Adolescents aged 15–19 years had the highest incidence of ischemic stroke. Non‐optimal temperature contributed the most to the DALYs and death rates for stroke. By 2050, it is projected that 282,404 DALYs will be lost due to stroke.Conclusions: Stroke burden varies by the GBD region, country, age, sex, and SDI. Despite declines in ASRs, stroke remains a significant burden, especially in middle‐to‐low‐SDI regions, among children < 1 year, and among those with intracerebral hemorrhage. Non‐optimal temperature emerges as the leading modifiable risk factor for children stroke; targeted interventions can prevent this.

9 December 2024 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
XWXiao‐Peng Wang
Xiao‐Peng Wang
JLJing‐Jie Li
Jing‐Jie Li
QWQian‐Nan Wang
Qian‐Nan Wang
GGGan Gao
Gan Gao
DYDan Yu
Dan Yu
LDLian Duan
Lian Duan
Background: Moyamoya disease (MMD) and moyamoya syndrome (MMS) are rare cerebrovascular conditions with unclear distinctions in clinical presentation and prognosis.Aim: This study assessed potential differences between MMD and MMS patients using real‐world data on clinical manifestations, surgical outcomes, and stroke risk factors.Methods: This multicenter, retrospective cohort study examined patients with MMD or MMS treated at three tertiary academic hospitals in China, with a mean follow‐up of 11.2 ± 3.1 years. Clinical differences were compared between MMD and MMS, and postoperative cerebrovascular events were compared between patients who underwent surgery and those with conservative management. Primary outcomes were postoperative ischemic and hemorrhagic strokes. Risk factors were evaluated via multivariate Cox regression analysis.Results: Of the 2565 patients, 2349 had MMD and 216 had MMS. After 1:1 propensity‐score matching, no significant differences were observed between these two cohorts. Surgical patients had fewer cerebrovascular events than those who received conservative treatment (HR, 0.487; 95% CI, 0.334–0.711; p < 0.001). Preadmission modified Rankin scale scores > 2 (HR, 3.139; 95% CI, 1.254–7.857; p = 0.015) and periprocedural complications (HR, 8.666; 95% CI, 3.476–21.604; p < 0.001) were independent stroke risk factors in patients with MMD. Periprocedural complications (HR, 31.807; 95% CI, 10.916–92.684; p < 0.001) increased stroke risk in patients with MMS.Conclusions: This real‐world study revealed substantial clinical overlap between MMD and MMS. Both groups derived significant benefits from surgical revascularization, suggesting distinction may not be necessary to guide surgical management decisions. Optimizing preoperative status and preventing periprocedural complications may improve outcomes in these rare cerebrovascular conditions.Trial Registration: This study has been registered in the Chinese Clinical trial registry (registration number: ChiCTR2200064160)

22 January 2022 in World Neurosurgery
Verified
Journal Article
Closed access
XWXiao-Peng Wang
Xiao-Peng Wang
XBXiang-Yang Bao
Xiang-Yang Bao
QWQian-Nan Wang
Qian-Nan Wang
ZZZheng-Xing Zou
Zheng-Xing Zou
RYRi-Miao Yang
Ri-Miao Yang
LDLian Duan
Lian Duan

6 August 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
XWXiao‐Peng Wang
Xiao‐Peng Wang
BRBin Ren
Bin Ren
QWQian‐Nan Wang
Qian‐Nan Wang
JLJing‐Jie Li
Jing‐Jie Li
JLJia‐Qi Liu
Jia‐Qi Liu
LDLian Duan
Lian Duan
Background: This study investigated the long‐term clinical and angiographic outcomes of encephaloduroarteriosynangiosis treatment for symptomatic intracranial atherosclerotic arterial steno‐occlusive disease to further evaluate the potential therapeutic role of encephaloduroarteriosynangiosis in this population. Methods and Results: A total of 152 adult patients with symptomatic intracranial atherosclerotic arterial steno‐occlusive disease who were treated with encephaloduroarteriosynangiosis and intensive medical management across 3 tertiary centers in China between January 2011 and September 2019 were retrospectively included. The primary outcomes were defined as postoperative cerebrovascular events, including ischemic and hemorrhagic stroke. The postoperative neovascularization was analyzed qualitatively and quantitatively by using angiography. Clinical, radiological, and long‐term follow‐up data were analyzed using Cox regression, logistic regression, and linear regression analyses. Primary outcome rates were 3.2% (5/152) within 30 days, 6.6% (10/152) within 2 years, 9.2% (14/152) within 5 years, and 11.1% (17/152) during a median 9.13 years follow‐up. Initial infarction symptoms were positively associated with recurrent ischemic stroke. Additionally, posterior circulation involvement and coexisting cardiac disease indicated poorer neurological status, whereas encephaloduroarteriosynangiosis neovascularization efficacy was negatively associated with older age and vascular risk factors but positively associated with posterior circulation involvement. Conclusions: Encephaloduroarteriosynangiosis plus intensive medical management appears efficacious and safe for symptomatic intracranial atherosclerotic arterial steno‐occlusive disease, with low perioperative risk and favorable long‐term results. Further prospective trials are needed to verify its efficacy and determine the optimal patient selection criteria.

9 March 2024 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
PDF file
SLSi-Meng Liu
Si-Meng Liu
GGGan Gao
Gan Gao
FHFang-Bin Hao
Fang-Bin Hao
SLShi-Tong Liu
Shi-Tong Liu
RYRi-Miao Yang
Ri-Miao Yang
LDLian Duan
Lian Duan
Background: The relationship between anterior cerebral artery (ACA) occlusion and moyamoya disease (MMD) has rarely been studied. In this study, we focused on a special type of MMD: isolated ACA-occlusive MMD. We investigated clinical attributes, genotypes and progression risk factors in patients with ACA-occlusive MMD, providing initial insights into the relationship between ACA occlusion and MMD.Methods: We retrospectively analysed digital subtraction angiography (DSA) from 2486 patients and diagnosed 139 patients with ACA-occlusive MMD.RNF213p.R4810K (rs112735431) mutation analysis was performed. Patients were categorised into progression and non-progression groups based on whether they progressed to typical MMD. Differences in clinical characteristics, neuropsychological assessment, radiological findings and genotypes were evaluated. Logistic regression analyses identified risk factors for ACA-occlusive MMD progression.Results: The median age of patients with ACA-occlusive MMD was 36 years, and the primary symptom was transient ischaemic attack (TIA). 72.3% of ACA-occlusive MMD patients had cognitive decline. Of 116 patients who underwentRNF213gene mutation analysis, 90 patients (77.6%) carried theRNF213p.R4810K GG allele and 26 (22.4%) carried the GA allele. Of 102 patients with follow-up DSA data, 40 patients (39.2%) progressed. Kaplan-Meier curve estimates indicated a higher incidence of ischaemic stroke in the progression group during follow-up (p=0.035). Younger age (p=0.041),RNF213p.R4810K GA genotype (p=0.037) and poor collateral compensation from the middle cerebral artery (MCA) to ACA (p<0.001) were risk factors of ACA-occlusive MMD progression to typical MMD.Conclusions: Cognitive decline and TIA might be the main manifestations of ACA-occlusive MMD. Isolated ACA occlusion may be an early signal of MMD. The initial lesion site of MMD is not strictly confined to the terminal portion of the internal carotid artery. Younger patients, patients withRNF213p.R4810K GA genotype or those with inadequate MCA-to-ACA compensation are more likely to develop typical MMD.

4 August 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
QGQingbao Guo
Qingbao Guo
MXManli Xie
Manli Xie
HWHui Wang
Hui Wang
JLJingjie Li
Jingjie Li
QWQian‐Nan Wang
Qian‐Nan Wang
LDLian Duan
Lian Duan
Background: Moyamoya disease (MMD) is a rare cerebrovascular disorder with unknown pathogenesis, partly due to limited access to human cerebral vascular tissue and suitable animal models. Using a large biobank of frozen serum samples, this study aimed to explore molecular signatures of ischemic and hemorrhagic MMD. Methods: Serum from 30 patients with MMD (18 ischemic, 12 hemorrhagic) and 30 matched healthy controls underwent proteomic and metabolomic profiling. Data were analyzed for differential expression, pathway enrichment, and protein–metabolite networks, with adjustment for age, sex, and body mass index. Results: In a separate large Chinese cohort (n=6167), female patients had a higher proportion of hemorrhagic MMD (19.9% versus 16.9%) and a higher prevalence of anterior choroidal artery dilation (15.1% versus 13.2%) than male patients (both P <0.05). At the molecular level, ischemic MMD showed complement C4‐B deficiency and disrupted natural killer cell cytotoxicity; both subtypes shared immunoglobulin perturbations (eg, decreased heavy‐chain variable regions). Sex‐specific alterations included anti–folate‐binding protein, serum amyloid A2, glycolithocholic acid, and estradiol. All omics data are publicly accessible. Conclusions: Integrated serum multiomics defines distinct immune‐related signatures for ischemic and hemorrhagic MMD and reveals sex‐dimorphic molecular pathways. These findings, together with clinical sex differences in disease subtype and vascular anatomy, provide a framework for personalized, sex‐aware management of MMD.